MBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences schedules September investor conference appearances with live and archived webcast access for investors.
Rhea-AI Summary
MBX Biosciences (MBX) will participate in two investor conferences in September 2026 featuring Chairman and CEO Steve Hoerter and Chief Medical Officer Sam Azoulay.
The company will join the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, with a fireside chat and 1x1 meetings from 8:30–9:05 a.m. ET. MBX will also take part in the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, holding a virtual fireside chat and 1x1 meetings from 11:00–11:25 a.m. ET. Live webcasts and 90-day replays will be accessible via the events section of the company’s investor website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Wednesday, September 16, 2026
Format: Fireside chat and 1x1 meetings
Time: 8:30 – 9:05 a.m. ET
Location: New York, NY
Stifel 2026 Virtual Cardiometabolic Forum
Date: Wednesday, September 30, 2026
Format: Virtual Fireside chat and 1x1 meetings
Time: 11:00 – 11:25 a.m. ET
The live webcasts can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow us on LinkedIn and X.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
Investor Contact:
Pete De Spain
MBX Biosciences
pdespain@mbxbio.com
FAQ
How can investors access the live MBX Biosciences conference webcasts?
Live webcasts of both conferences can be accessed in the events section of the MBX Biosciences investor website at https://investors.mbxbio.com/news-events/events.
Will replays of the MBX Biosciences presentations be available after the conferences?
Webcast replays will be available approximately two hours after each event and will remain archived on the company’s website for about 90 days.